HIGHBuilt-inProduct / Revenue mix
83%
iStent family and iDose TR glaucoma franchise
“10-K Item 1: 'our iStent family of products, iDose TR, and related glaucoma accessories accounted for approximately 83% of our net sales'”
GKOS · Concentration risk · 10-K extracted
Glaukos (GKOS) concentration risks
Updated
The most significant concentration Glaukos discloses is iStent family and iDose TR glaucoma franchise at 83%, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Glaukos’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 4 disclosed concentrations
HIGH4
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHBuilt-inGeographic
74%
U.S. customers
“10-K Item 1: 'sales to U.S. and international customers accounted for 74% and 26% of our net sales, respectively'”
HIGHBuilt-inSupplier
sole manufacturing campus in San Clemente
“10-K Item 1A: 'Our sole manufacturing location for our iStent and iDose products is an approximately 120,000 square foot campus located in San Clemente, California'”
HIGHOutside partySupplier
sole third-party component suppliers
“10-K Item 1A: 'we rely on a limited number of third-party suppliers, in some cases sole suppliers, to supply components for the iStent, the iStent inject models, the iStent infinite, the iDose TR'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's disclosed concentration profile is among the most layered in the medtech peer group, with large exposures on both the product, geographic, and supply sides. The iStent family of products, iDose TR, and related glaucoma accessories accounted for approximately 83% of net sales — a large share by disclosed size that is structural in character. The company is fundamentally a glaucoma franchise; nearly all revenue derives from a narrow set of ophthalmic surgical implants targeting that single therapeutic area. Sales to U.S. customers accounted for 74% of net sales — also a large share by disclosed size and structural in character — reflecting where the primary commercial infrastructure and surgical adoption are concentrated. On the manufacturing side, the sole manufacturing location for iStent and iDose products is a single campus in San Clemente, California — a large concentration by disclosed size. A facility disruption at that location — from a natural disaster, regulatory action, or operational failure — would directly threaten the company's ability to supply the products that generate the vast majority of its revenue. Compounding this, the company relies on a limited number of third-party suppliers, in some cases sole suppliers, for components across the iStent, iStent inject, iStent infinite, and iDose TR product lines — another large dependency by disclosed size. Together, these four exposures reinforce each other: a highly concentrated product portfolio, U.S.-centric revenue, a sole manufacturing site, and sole-source component suppliers create a profile with limited redundancy across the critical operating dimensions.
For the engine’s reasoning on GKOS’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Devices
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| AORT | Artivion, Inc. | 4 | 4 | 0 | 8 |
| GKOS● | Glaukos Corporation | 4 | 0 | 0 | 4 |
| ATEC | Alphatec Holdings, Inc. | 1 | 1 | 0 | 2 |
| ABT | Abbott Laboratories | 1 | 0 | 0 | 1 |
| AXGN | AxoGen, Inc. | 0 | 0 | 0 | 0 |
| BIO | Bio-Rad Laboratories, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.